Anti-fungal drug may help treat cancer

(Santa Barbara, Calif.) - A drug that has been used for 40 years for the treatment of skin fungus has been found to be a possible cancer treatment, according to an international team of scientists. Leslie Wilson, professor of biochemistry and pharmacology at the University of California, Santa Barbara, said that the antifungal drug, griseofulvin, has been shown to inhibit the growth of cancer cells in his laboratory. The results are published in today's online edition of the Proceedings of the National Academy of Sciences.

The work is the result of a collaboration between Wilson's lab, in UCSB's Department of Biochemistry, Molecular, Cellular and Developmental Biology, and a lab in the School of Biosciences and Bioengineering of the Indian Institute of Technology Bombay, in India.

"The drug has remarkably few side effects and has been used for a long time," said Wilson. Griseofulvin is administered orally, and has been used for decades to treat ringworm and other fungal infections of the skin.

"We discovered that it has the ability to inhibit the growth of cancer cells, in a manner that is similar to much more powerful anticancer drugs such as taxol and vinblastine," said Wilson. "Although the anti-cancer activity is weak, it is already approved for human use and could be used along with more powerful anticancer agents as an adjuvant in cancer chemotherapy."

The authors found that the drug inhibits the proliferation of cancer cells by affecting mitosis, or cell division, and mitotic spindle microtubule function. They conclude: "A mild suppression of microtubule dynamics by griseofulvin in tumor cells, combined with the effects of more powerful drugs working through other mechanisms, might provide a therapeutic advantage for treatment of certain tumors."


Contact: Gail Gallessich
University of California - Santa Barbara

Page: 1

Related biology news :

1. Anti-fungal drug kills TB bug
2. New system of wastewater treatment could reduce the size of treatment plants by half
3. Brain blood flow gives clues to treating depression
4. UCF research links proteins, stem cells and potential Alzheimers treatment
5. New strategy for treating allergic disorders
6. Geisinger scientist seeks cure for Lou Gehrigs disease, creating device to find treatment
7. System to analyze beating heart stem cells could lead to heart attack treatments
8. Gene expression pattern could lead to improved treatment of pediatric septic shock
9. Molecular detectors may refine cancer treatment
10. First genome-wide study of infectious disease opens new avenues for HIV treatment, vaccines
11. A new method of adult stem cell growth efficacious in treatment of disorders of the cornea

Post Your Comments:

(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/16/2016)... , June 16, 2016 ... is expected to reach USD 1.83 billion by ... View Research, Inc. Technological proliferation and increasing demand ... are expected to drive the market growth. ... The development of advanced multimodal techniques ...
(Date:6/3/2016)... , June 3, 2016 ... Management) von Nepal ... und Lieferung hochsicherer geprägter Kennzeichen, einschließlich Personalisierung, ... führend in der Produktion und Implementierung von ... der Ausschreibung im Januar teilgenommen, aber Decatur ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
(Date:6/23/2016)... , June, 23, 2016  The Biodesign Challenge (BDC), ... new ways to harness living systems and biotechnology, announced ... (MoMA) in New York City . ... participating students, showcased projects at MoMA,s Celeste Bartos Theater ... Antonelli , MoMA,s senior curator of architecture and design, ...
(Date:6/23/2016)... Apellis Pharmaceuticals, Inc. today announced positive ... its complement C3 inhibitor, APL-2. The trials were ... studies designed to assess the safety, tolerability, pharmacokinetics ... healthy adult volunteers. Forty subjects were ... dose (ranging from 45 to 1,440mg) or repeated ...
(Date:6/23/2016)... ... June 23, 2016 , ... Regulatory Compliance Associates® Inc. ... a free webinar on Performing Quality Investigations: Getting to Root Cause. ... at no charge. , Incomplete investigations are still a major concern to the ...
Breaking Biology Technology:
Cached News: